Two additional phase II studies are currently ongoing to evaluate the tracer in non-breast tumors and breast cancer patients undergoing neoadjuvant therapy (NCT03924466), as well as in HER2+ brain metastases (NCT03331601). This evidence concerns the gene ERBB2 and breast carcinoma.